On June 8, the official website of the National Medical Products Administration (NMPA) showed that RemeGen's telitacicep was approved for two new indications: the treatment of primary Sjögren's syndrome (pSS) and primary immunoglobulin A (IgA) nephropathy. The drug is the first biologic approved globally in the Sjögren's syndrome field.
Telitacicep is a first-in-class recombinant B lymphocyte stimulator (BLyS)/A proliferation-inducing ligand (APRIL) dual-target fusion protein independently developed by RemeGen. It works by simultaneously inhibiting the binding of BLyS and APRIL to B-cell surface receptors, preventing abnormal B-cell differentiation and maturation, and effectively alleviating pathological immune responses in the body.
On June 25, 2025, RemeGen granted Vor Biopharma exclusive rights to develop, manufacture, and commercialize telitacicep worldwide outside Greater China, receiving $125 million in cash and warrants (including a $45 million upfront payment and $80 million in warrants, exercisable at $0.0001 per share to subscribe for 320 million common shares of Vor Bio, representing approximately 23% of Vor Bio's enlarged total issued share capital), milestone payments of up to $4.105 billion, with a total deal value of $4.23 billion. In addition, RemeGen will receive high single-digit to double-digit sales royalties.
In August 2025, the Phase III clinical study of telitacicep for pSS reached its primary endpoint. Study results showed that patients in the telitacicep group had a significantly greater reduction in disease activity score compared with the placebo group (-4.4 vs -0.6, P<0.0001).
Also in August of the same year,the domestic Phase III clinical study of telitacicep for primary IgA nephropathy reached the primary endpoint of Stage A. Study results showed that compared with the placebo group, patients in the telitacicep group had a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at Week 39 of treatment (P<0.0001).
According to the PharmCube database, telitacicep has currently been approved for five indications in China; the other three are systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis.
Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and exocrine gland damage. In addition to persistent dry mouth and dry eyes caused by salivary and lacrimal gland dysfunction, it can also involve multiple organ systems. The prevalence of Sjögren's syndrome in China is 0.3%–0.7%, and it is on the rise, representing a significant unmet clinical need.
IgA nephropathy is one of the most common primary glomerular diseases worldwide. According to Frost & Sullivan estimates, the global IgA nephropathy patient population will reach 10.16 million by 2030, including 2.37 million in China. IgA nephropathy patients in China account for approximately 54.3% of all renal biopsy cases, with 30%–40% of patients progressing to end-stage renal disease (ESRD). The disease burden is substantial, but effective therapies are scarce, and there is an urgent clinical need for novel drugs to treat IgA nephropathy.